Contact Us
Drug Search Results
More Filters [+]

Vorsetuzumab mafodotin

Alternative Names: vorsetuzumab mafodotin, denintuzumab mafodotin, sgn-cd19a, sgn-75, abt-414
Latest Update: 2024-02-20
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Tubulin Inhibitor,Mitosis Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vorsetuzumab mafodotin

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czech Republic, France, Germany, Hong Kong, Ireland, Israel, Italy, Korea, Mexico, Netherlands, New Zealand, Portugal, Russia, Singapore, South Africa, Spain, Switzerland, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Glioblastoma|Gliosarcoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2015-001166-26

P3

Completed

Glioblastoma|Gliosarcoma

2022-04-04

Intellance1

P3

Completed

Glioblastoma|Gliosarcoma

2022-04-04

Recent News Events

Date

Type

Title

02/20/2024

PubMed

 Efficacy of Depatuxizumab Mafodotin (ABT-414) in preclinical models of head and neck cancer.

07/12/2022

PubMed

 Biodistribution Analysis of an Anti-EGFR Antibody in the Rat Brain: Validation of CSF Microcirculation as a Viable Pathway to Circumvent the Blood-Brain Barrier for Drug Delivery.

02/28/2022

PubMed

 Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.

05/30/2019

News Article

 AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings

05/17/2019

News Article

 AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions